Life sciences venture capital group Abingworth Management has chosen Michelle Doig to advise it on funding and re-financing its portfolio companies. She is based in London, UK. Doig was formerly director, corporate finance and advisory, at Bioscience Managers, where she advised UK and European life science companies on strategic, m&a and financial transactions.
The Celltech group has named Daniel Greenleaf as president, US operations, based at its Rochester, NY, facility. He will lead the US organisation in the commercialisation of pipeline products and in driving the growth of the existing portfolio. Greenleaf has held a number of senior positions in the biotech and pharmaceutical industries, including at Nabi Biopharmaceuticals and Schering-Plough Corporation.
Tracy Small has been appointed sales manager at RSSL Pharma, the pharmaceutical advisory, training and consultancy division of Reading Scientific Services Ltd (RSSL). She was previously deputy technical manager for RSSL Pharma's pharmaceutical laboratory.
Biopharmaceutical company Antisoma has appointed Dr Ursula Ney as chief operating officer. She will oversee the company's established drug development programmes and business development activities. She has also been appointed to the Board of Antisoma.
Suncombe, the UK manufacturer of high tech sterile processing systems, has appointed Ian Litchfield as sales manager with special responsibility for the pharmaceutical market.
After 14 years as ceo, Soren Mouritsen has expressed his wish to leave Pharmexa to seek new challenges. His place at the head of the Danish company is to be taken by the current chief financial officer, Jakob Schmidt.
Clariant has announced the appointment of Dr Hubert Bader as the head of Clariant Custom Synthesis - the custom synthesis business unit of Clariant's life sciences and electronic chemicals division. Dr Bader has had a long and distinguished career with Clariant in a wide range of technical and management positions. He will work out of Clariant's Sulzbach (Frankfurt), Germany location.
Invitrogen has named Dr Michael Stapleton as general manager and vice president of its bioinformatics business. Additionally, the company named Dr Vivien Bonazzi, director, research and development, bioinformatics.